Outlook Therapeutics Prices $55M Public Offering with Warrants at $0.99

summarizeSummary

Outlook Therapeutics priced a $55 million public offering of 55.6 million shares plus warrants at $0.99 per unit, with net proceeds of about $51.1 million to fund the US launch of LYTENAVA.

check_boxKey Events · Financing and Capital Events · OTLK

• Public Offering Priced

  55,555,556 shares plus warrants to purchase 55,555,556 shares at combined price of $0.99 per share, for total gross proceeds of $55.0 million.

• Net Proceeds and Use

  Net proceeds of approximately $51.1 million after underwriting discounts and expenses, to fund US commercial launch of LYTENAVA and working capital.

• Warrant Terms

  Warrants exercisable immediately at $1.10 per share, expire five years from issuance; underwriters have 30-day option for 8,333,333 additional shares/warrants.

• Dilution Impact

  Offering increases outstanding shares from 187.1 million to 242.7 million, a 29.7% increase; immediate dilution of $0.75 per share to new investors.

auto_awesomeAnalysis · OTLK · Life Sciences

Outlook Therapeutics is raising $55 million in a public offering of 55.6 million shares plus warrants, priced at $0.99 per unit. The deal is highly dilutive — the offering nearly doubles the current share count of 187 million — but it provides critical capital to fund the US commercial launch of LYTENAVA, which received FDA approval in July 2026. The company had only $11.2 million in cash as of June 30, 2026, and this raise extends its runway into Q2 2027. The warrants, exercisable at $1.10, add further potential dilution if the stock rises. The offering price is below the last reported sale price of $1.10 on August 12, 2026, indicating a discount to market.